Primary Site >> Liver Cancer
Gene >> FGF19
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. PMID: 12057932 |
Ref: Comparative genomics on mammalian Fgf3-Fgf4 locus. PMID: 15942670 |
Ref: Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. PMID: 17599042 Ref: Mini-review: endocrine actions of fibroblast growth factor 19. PMID: 18179175 |
Ref: FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. PMID: 20018895 Ref: Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation. PMID: 20657013 |
Ref: Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. PMID: 21397858 |
Ref: Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys. PMID: 22268002 Ref: Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. PMID: 22309595 Ref: FGF19 and cancer. PMID: 22396170 Ref: Understanding the structure-function relationship between FGF19 and its mitogenic and metabolic activities. PMID: 22396171 Ref: Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PMID: 22615798 Ref: Regulation of amphiregulin gene expression by beta-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system. PMID: 23285165 |
Ref: Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma. PMID: 23456506 Ref: Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma. PMID: 24379610 |
Ref: Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations. PMID: 24393342 Ref: Regulation of bile acid homeostasis by the intestinal Diet1-FGF15/19 axis. PMID: 24535283 Ref: Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. PMID: 24589894 Ref: Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19. PMID: 24728076 Ref: Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. PMID: 24798001 Ref: Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. PMID: 24931142 |
Ref: Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development. PMID: 25346390 Ref: Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target. PMID: 25547779 Ref: Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. PMID: 25608663 Ref: Targeting FGF19 binding to its receptor system: a novel therapeutic approach for hepatocellular carcinoma. PMID: 25677789 Ref: First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. PMID: 25776529 Ref: Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. PMID: 25822088 Ref: Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR Agents. PMID: 25847957 Ref: Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. PMID: 26099527 Ref: New molecular therapies for hepatocellular carcinoma. PMID: 26206572 Ref: Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. PMID: 28943626 |
Ref: FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3beta/beta- catenin signaling cascade via FGFR4 activation. PMID: 26498355 Ref: Mechanistic target of rapamycin complex 1 is an essential mediator of metabolic and mitogenic effects of fibroblast growth factor 19 in hepatoma cells. PMID: 27178107 Ref: Whole-genome DNA methylation and hydroxymethylation profiling for HBV-related hepatocellular carcinoma. PMID: 27221337 Ref: FGF19 functions as autocrine growth factor for hepatoblastoma. PMID: 27382436 Ref: Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. PMID: 27384874 Ref: Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma. PMID: 27447573 |
Ref: Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents. PMID: 27639803 Ref: ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma. PMID: 27837028 Ref: FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. PMID: 28069043 Ref: Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation. PMID: 28178326 Ref: Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15. PMID: 28189755 Ref: Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis. PMID: 28249259 Ref: Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma. PMID: 28445152 Ref: Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. PMID: 28508871 Ref: Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. PMID: 28532995 Ref: FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3beta-Nrf2 Signaling. PMID: 28951455 Ref: H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma. PMID: 29247039 Ref: Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. PMID: 29404440 |
Ref: Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report. PMID: 28983785 Ref: Endocrine Adiponectin-FGF15/19 Axis in Ethanol-Induced Inflammation and Alcoholic Liver Injury. PMID: 29096734 Ref: Bile Acid Sequestration by Cholestyramine Mitigates FGFR4 Inhibition-Induced ALT Elevation. PMID: 29432567 Ref: Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. PMID: 29460642 Ref: The ileal FGF15/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice. PMID: 29468415 Ref: Research progress on the forkhead box C1. PMID: 29552326 Ref: Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. PMID: 29733511 Ref: Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver. PMID: 29973237 Ref: The gut-liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19. PMID: 30223181 Ref: Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies. PMID: 30373752 |